Insider Trading Alert - JMP, LDL And ALQA Traded By Insiders

Yesterday, Nov. 9, 2015, 81 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,037.40 to $6,950,097.00.

Highlighted Stocks Traded by Insiders:

JMP Group (JMP) - FREE Research Report

Tongue Glenn H, who is Director at JMP Group, bought 7,000 shares at $6.19 on Nov. 9, 2015. Following this transaction, the Director owned 124,815 shares meaning that the stake was boosted by 5.94% with the 7,000-share transaction.

The shares most recently traded at $6.45, up $0.26, or 4.08% since the insider transaction. Historical insider transactions for JMP Group go as follows:

  • 4-Week # shares bought: 12,000
  • 12-Week # shares bought: 12,000
  • 24-Week # shares bought: 12,000

The average volume for JMP Group has been 46,400 shares per day over the past 30 days. JMP Group has a market cap of $134.1 million and is part of the financial sector and financial services industry. Shares are down 15.75% year-to-date as of the close of trading on Monday.

JMP Group LLC, together with its subsidiaries, provides investment banking and asset management services in the United States. The company operates through Broker-Dealer, Asset Management, and Corporate Credit segments. The stock currently has a dividend yield of 7.59%. The company has a P/E ratio of 26.3. Currently, there are 2 analysts who rate JMP Group a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on JMP - FREE

TheStreet Quant Ratings rates JMP Group as a hold. The company's strongest point has been its expanding profit margins. At the same time, however, we also find weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and disappointing return on equity. Get the full JMP Group Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Lydall (LDL) - FREE Research Report

Burdett Kathleen, who is Director at Lydall, sold 4,833 shares at $37.12 on Nov. 9, 2015. Following this transaction, the Director owned 44,809 shares meaning that the stake was reduced by 9.74% with the 4,833-share transaction.

The shares most recently traded at $35.50, down $1.62, or 4.56% since the insider transaction. Historical insider transactions for Lydall go as follows:

  • 4-Week # shares sold: 5,000
  • 12-Week # shares sold: 5,000
  • 24-Week # shares sold: 5,000

The average volume for Lydall has been 81,300 shares per day over the past 30 days. Lydall has a market cap of $613.5 million and is part of the consumer goods sector and automotive industry. Shares are up 7.59% year-to-date as of the close of trading on Monday.

Lydall, Inc designs and manufactures specialty engineered filtration media, industrial thermal insulating solutions, and automotive thermal and acoustical barriers worldwide. The company has a P/E ratio of 13.2. Currently, there are no analysts who rate Lydall a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LDL - FREE

TheStreet Quant Ratings rates Lydall as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and attractive valuation levels. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full Lydall Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Alliqua BioMedical (ALQA) - FREE Research Report

Leone Joseph M, who is Director at Alliqua BioMedical, bought 3,500 shares at $2.78 on Nov. 9, 2015. Following this transaction, the Director owned 18,823 shares meaning that the stake was boosted by 22.84% with the 3,500-share transaction.

Zeldis Jerome B, who is Director at Alliqua BioMedical, bought 14,000 shares at $2.91 on Nov. 9, 2015. Following this transaction, the Director owned 286,750 shares meaning that the stake was boosted by 5.13% with the 14,000-share transaction.

Johnson David Ian, who is President and CEO at Alliqua BioMedical, bought 8,650 shares at $2.92 on Nov. 9, 2015. Following this transaction, the President and CEO owned 584,603 shares meaning that the stake was boosted by 1.5% with the 8,650-share transaction.

Barton Bradford, who is Chief Operating Officer at Alliqua BioMedical, bought 5,000 shares at $2.97 on Nov. 9, 2015. Following this transaction, the Chief Operating Officer owned 120,985 shares meaning that the stake was boosted by 4.31% with the 5,000-share transaction.

Pionati Pellegrino, who is Chief Strategy & Marketing Off at Alliqua BioMedical, bought 10,000 shares at $2.95 on Nov. 9, 2015. Following this transaction, the Chief Strategy & Marketing Off owned 116,512 shares meaning that the stake was boosted by 9.39% with the 10,000-share transaction.

The shares most recently traded at $2.98, up $0.03, or 1.01% since the insider transaction. Historical insider transactions for Alliqua BioMedical go as follows:

  • 4-Week # shares bought: 2,500
  • 12-Week # shares bought: 2,500
  • 24-Week # shares bought: 15,500

The average volume for Alliqua BioMedical has been 67,500 shares per day over the past 30 days. Alliqua BioMedical has a market cap of $81.6 million and is part of the health care sector and drugs industry. Shares are down 44.34% year-to-date as of the close of trading on Monday.

Alliqua BioMedical, Inc. provides wound care solutions. Currently, there are 5 analysts who rate Alliqua BioMedical a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ALQA - FREE

TheStreet Quant Ratings rates Alliqua BioMedical as a sell. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow, generally disappointing historical performance in the stock itself and unimpressive growth in net income. Get the full Alliqua BioMedical Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%